StockTipsArenaBeta

BUY Piramal Pharma Limited — Pradip Hotchandani, Prudent Corporate Advisory Services

BUYPiramal Pharma Limited

byPradip Hotchandani, Prudent Corporate Advisory ServicesHorizon: NA (inferred Swing (≤2wk))28 Aug 2026via CNBC Awaaz.

Entry₹218.76Inferred
Target₹250
Total upside +14.28% (call closed)
Stop loss₹211-3.55% risk
Exit₹2111 Sept 2026, 10:35 am
Stop-loss hit-3.55%
Follow Pradip Hotchandani for new calls(22% target hit, 37 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 1 active Swing call on PPLPHARMASee 274 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 1 Sept 2026
7 supporting3 neutral2 opposing
Supports the BUY call (7)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·27 Aug · 4d ago

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

NewsGoogle News·26 Aug · 5d ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·26 Aug · 5d ago

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited

NewsGoogle News·24 Aug · 1w ago

(opens in new tab)

Yapan Bio to become Piramal subsidiary following acquisition

NewsGoogle News·20 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (3)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 4d ago

(opens in new tab)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 4d ago

(opens in new tab)

Piramal Pharma emphasises sustainability in FY 2025-26 report

NewsGoogle News·24 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (2)

Piramal Pharma reports 22.6% drop in Scope 1 & 2 emissions for FY26

NewsGoogle News·24 Aug · 1w ago

(opens in new tab)

Piramal Pharma block deal likely cancelled; stock falls 3%

NewsCnbc-Tv18·14 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.